IMTX
What one share of Immatics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities.
Immatics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$1.82 |
|---|---|
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$1.69 |
| Cash and investments | $3.03 |
| Book value | $4.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$1.12 | $0.02 | $0.72 | — | −$0.32 |
| 2019 | — | −$1.07 | $0.07 | $2.33 | — | −$1.42 |
| 2020 | — | −$5.02 | $0.18 | −$2.09 | — | $1.70 |
| 2021 | — | −$1.76 | $0.10 | −$1.69 | — | $0.43 |
| 2022 | — | $0.42 | $0.09 | $1.44 | — | $2.84 |
| 2023 | — | −$1.27 | $0.41 | −$0.17 | — | $2.84 |
| 2024 | — | $0.15 | $0.16 | −$1.77 | — | $4.90 |
| 2025 | — | −$1.82 | $0.06 | −$1.69 | — | $4.24 |